乳腺癌的化疗及靶向治疗ppt课件.ppt

乳腺癌的化疗及靶向治疗 解放军总医院肿瘤中心 ; ;Copyright ?2005 American Association for Cancer Research;;乳腺癌化疗药物的进展 ;1976;;1976;含蒽环类方案 VS CMF;1976;;;紫杉类乳腺癌辅助化疗第一代随机临床试验：总结;US Oncology: Are Anthracyclines Essential?;AC vs TC Jones, JCO 2006;紫杉类乳腺癌辅助化疗;Ax4—Tx4—Cx4 3周续贯 36周;Dose-Dense v Conventional Chemotherapy;ECOG 1199 研究设计;E1199：无病生存;E1199：总生存曲线;;BCIRG 001 “TAC (DAC) vs FAC”; Overall Survival (ITT);FEC vs FEC → Paclitaxel;1976;NSABP B-31;Romond, E. H. et al. N Engl J Med 2005;353:1673-1684;;DISEASE-FREE SURVIVAL;4 x AC60/600 mg/m2;Disease Free Survival - 2nd Interim Analysis;Overall Survival – 2nd Interim Analysis;Cardiac Deaths and CHF as per Independent Review Panel;倾向 非赫赛汀?治疗 ;;440mg 冻干粉针剂 20ml 无菌注射用水; ;乳腺癌辅助治疗的进展;浸润性乳腺癌 常用的术后辅助化疗方案;;;复发转移性乳腺癌的化疗原则;晚期乳腺癌治疗的进展;分层: DFI 24 mos. vs. 24 mos. 3 vs. 3 metastatic sites Adjuvant chemotherapy yes vs. no ER+ vs. ER- vs. ER unknown;E2100: 缓解率;E2100: 无进展生存;E2100:总生存;结论;Lapatinib;Lapatinib Monotherapy in Previously Treated Metastatic Breast Cancer;EGF100151 Study Design;Time to Progession as Assessed by IRC;Response Rate – ITT Population ;埃坡霉素：Ixabepilone;研究设计：随机、III期临床试验;缓解率;Grade 3/4 血液学毒性;非血液学毒性;结论;晚期乳腺癌的治疗;;